💊💉 #anakinra
SmPC for Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology and method of administration; 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 6.5 Nature and contents of container; 10. Date of revision of the text on 23/02/2024.
🌐 https://www.medicines.org.uk/emc/product/559/smpc
Change log: https://www.medicines.org.uk/emc/product/559/smpc/history
Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)

Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC) by Swedish Orphan Biovitrum Ltd

I'm now keeping an eye on: The SmPC for Kineret 100 mg solution for injection in a pre-filled syringe

🏭Swedish Orphan Biovitrum Ltd

💊💉 #anakinra.

I will let you know if it changes.

🌐 https://www.medicines.org.uk/emc/product/559/smpc

Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)

Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC) by Swedish Orphan Biovitrum Ltd

No Benefit of Anti-inflammatory Strategy in Acute Myocarditis
A short course of the interleukin-1 receptor antagonist, anakinra, appeared safe but did not reduce complications of acute myocarditis in the ARAMIS trial.
https://www.medscape.com/viewarticle/996176? #AntiInflammatory #myocarditis #interleukin1 #anakinra #ARAMIS
No Benefit of Anti-inflammatory Strategy in Acute Myocarditis

A short course of the interleukin-1 receptor antagonist, anakinra, appeared safe but did not reduce complications of acute myocarditis in the ARAMIS trial.

Medscape
Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19

This randomized clinical trial assesses the efficacy and safety of anakinra vs standard of care alone in patients with severe COVID-19 pneumonia and hyperinflammation.

Une équipe discrète pour un travail intéressant contre le #Covid_19 : l'#anakinra.
On appréciera l'humilité de la conclusion:
"This report has limitations, such as the low number of patients and being a retrospective study"
https://www.pnas.org/content/117/32/18951